J. Eng-Wong

发表

Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer

Mitchell H. Gail, Claudia Giambartolomei, Gretchen L. Gierach, 2010, Breast Cancer Research and Treatment.

A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer

D. Venzon, K. Cowan, J. O’Shaughnessy, 2003, Breast Cancer Research and Treatment.

Gynecologic and hormonal effects of raloxifene in premenopausal women.

D. Venzon, M. Forman, A. Remaley, 2007, Fertility and sterility.

Effects of Raloxifene on Circulating Prolactin and Estradiol Levels in Premenopausal Women at High Risk for Developing Breast Cancer

D. Venzon, S. Prindiville, J. Zujewski, 2006, Cancer Epidemiology Biomarkers & Prevention.

PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting.

A. Urruticoechea, I. Láng, S. Im, 2016 .

The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms

J. Eng-Wong, Sandra J Allison, V. Shanmugam, 2011, Breast Cancer Research and Treatment.

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

Junjie Li, S. Kang, Z. Shao, 2020, JAMA oncology.

Premenopausal Breast Cancer: Estrogen Receptor Status and Insulin‐Like Growth Factor‐I (IGF‐I), Insulin‐Like Growth Factor Binding Protein‐3 (IGFBP‐3), and Leptin

Donghui Li, M. Bondy, S. Perkins, 2009, The breast journal.

The impact of systemic therapy following ductal carcinoma in situ.

J. Costantino, S. Swain, J. Eng-Wong, 2010, Journal of the National Cancer Institute. Monographs.

Mammographic density does not differ between unaffectedBRCA1/2mutation carriers and women at low-to-average risk of breast cancer.

M. Gail, M. Greene, G. Gierach, 2009 .

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018, The Lancet. Oncology.

Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer

A. Daemen, J. Giltnane, M. Hafner, 2022, Science Translational Medicine.

Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).

J. Tabernero, Yoon-Koo Kang, A. Ohtsu, 2013 .

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study

M. Kågedal, C. Wynne, I. Nijem, 2018, Journal of clinical pharmacology.

616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

J. Tabernero, P. Hoff, J. Eng-Wong, 2017 .

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer

Sheila Prindiville, Claudia E. Galbo, D. Venzon, 2008, Cancer Epidemiology Biomarkers & Prevention.

A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.

D. Venzon, F. Balis, B. Widemann, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patient Navigation Significantly Reduces Delays in Breast Cancer Diagnosis in the District of Columbia

R. Brem, S. Swain, P. Levine, 2012, Cancer Epidemiology, Biomarkers & Prevention.

A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer.

M. Merino, F. Balis, B. Widemann, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women

B. Peshkin, V. Sheppard, D. Mays, 2012, Familial Cancer.

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Dae-Ho Lee, Jeeyun Lee, S. Monemi, 2021 .

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

S. Fox, S. Loi, J. Baselga, 2017, The Lancet. Oncology.

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety

C. Isaacs, D. Venzon, E. Makariou, 2016, Cancer Prevention Research.

Sentinel lymph node biopsy in the management of ductal carcinoma in situ.

J. Zujewski, J. Eng-Wong, J. Eng‐Wong, 2005, Clinical breast cancer.

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

S. Swain, G. Viale, S. Delaloge, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.

D. Venzon, J. Zujewski, S. Perkins, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.

A. Urruticoechea, I. Láng, S. Im, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of benefit from adjuvant treatment in patients with breast cancer.

C. Isaacs, J. Eng-Wong, J. Eng‐Wong, 2010, Clinical Breast Cancer.

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

Minetta C. Liu, C. Isaacs, G. Chung, 2010, Breast Cancer Research and Treatment.